Inhibition of myeloperoxidase oxidant production by N-acetyl lysyltyrosylcysteine amide reduces brain damage in a murine model of stroke by Guoliang Yu et al.
RESEARCH Open Access
Inhibition of myeloperoxidase oxidant
production by N-acetyl lysyltyrosylcysteine
amide reduces brain damage in a murine
model of stroke
Guoliang Yu1, Ye Liang1, Ziming Huang1,2, Deron W. Jones1, Kirkwood A. Pritchard Jr.1 and Hao Zhang1*
Abstract
Background: Oxidative stress plays an important and causal role in the mechanisms by which ischemia/reperfusion
(I/R) injury increases brain damage after stroke. Accordingly, reducing oxidative stress has been proposed as a
therapeutic strategy for limiting damage in the brain after stroke. Myeloperoxidase (MPO) is a highly potent
oxidative enzyme that is capable of inducing both oxidative and nitrosative stress in vivo.
Methods: To determine if and the extent to which MPO-generated oxidants contribute to brain I/R injury, we
treated mice subjected to middle cerebral artery occlusion (MCAO) with N-acetyl lysyltyrosylcysteine amide (KYC), a
novel, specific and non-toxic inhibitor of MPO. Behavioral testing, ischemic damage, blood-brain-barrier disruption,
apoptosis, neutrophils infiltration, microglia/macrophage activation, and MPO oxidation were analyzed within a
7-day period after MCAO.
Results: Our studies show that KYC treatment significantly reduces neurological severity scores, infarct size, IgG
extravasation, neutrophil infiltration, loss of neurons, apoptosis, and microglia/macrophage activation in the brains
of MCAO mice. Immunofluorescence studies show that KYC treatment reduces the formation of chlorotyrosine
(ClTyr), a fingerprint biomarker of MPO oxidation, nitrotyrosine (NO2Tyr), and 4-hydroxynonenal (4HNE) in MCAO
mice. All oxidative products colocalized with MPO in the infarcted brains, suggesting that MPO-generated oxidants
are involved in forming the oxidative products.
Conclusions: MPO-generated oxidants play detrimental roles in causing brain damage after stroke which is
effectively reduced by KYC.
Keywords: Stroke, Myeloperoxidase, Oxidative stress, N-acetyl lysyltyrosylcysteine amide (KYC), Middle cerebral
artery occlusion (MCAO)
Background
Oxidative stress is considered as an important, causal
factor in the mechanisms by which stroke induces brain
injury [1, 2]. Extensive studies have shown that the
increase in oxidative stress induced by I/R after acute
stroke plays a critical role in brain tissue injury. Immedi-
ately after acute ischemic stroke, reactive oxygen species
(ROS) and reactive nitrogen species (RNS) production
increases rapidly, resulting in severe damage to ischemic
tissues. Moreover, restoring blood flow to ischemic
tissue (reperfusion) induces even greater increases in
ROS/RNS production [3], which can induce more severe
tissue injury. Production of ROS, such as hydroxyl radi-
cals [4], superoxide (O2
−●) [5], peroxynitrite (ONOO−)
[6], and hydrogen peroxide (H2O2) [7], have all been
reported to be increased in animal models of stroke.
Consequently, oxidation products are increased in stroke
models [8]. Moreover, plasma levels of protein carbonyls
are increased in stroke patients as well as lipid peroxidation
products [9, 10]. Importantly, plasma malondialdehyde
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(MDA) levels in stroke patients appear to correlate with
their stroke severity and clinical outcomes [11, 12]. Taken
together, these reports strongly support the idea that ROS
and RNS play important roles in the mechanisms by which
stroke induces and propagates tissue injury and brain cell
death after stroke.
Although a considerable amount of evidence exists for
oxidative stress inducing neuronal damage in stroke,
clinical trials have failed to show that antioxidants sig-
nificantly improve outcomes [13–15]. Exactly why is still
unclear although several reasons have been proposed
(for details see [13–15]). One of the conclusions from
those studies is that agents targeting specific sources of
oxidative stress may be more effective for therapy for
stroke than a general antioxidant.
Until recently, the role of myeloperoxidase (MPO) in
stroke has been limited to serving as a biomarker for
neutrophil infiltration. MPO is a highly versatile oxida-
tive enzyme, capable of inducing both oxidative and
nitrosative stress in vivo [16]. After activation with
H2O2, MPO oxidizes substrates (chloride (Cl¯), bromide
(Br¯), nitrite (NO2¯), tyrosine (Tyr), etc.) to potent oxi-
dants (hypochlorous acid (HOCl) or hypobromous acid
(HOBr)) and free radicals (nitrogen dioxide (●NO2) or
tyrosyl radical (Tyr●) etc.), respectively. These free radi-
cals and oxidants are more potent than O2
−● and H2O2
for oxidizing biomolecules and inducing cellular injury
[16]. Although MPO is rapidly released from activated
neutrophils, monocytes, and some macrophages upon
activation [17], MPO is also expressed by activated
microglia, astrocytes, and certain types of neurons in
neurodegenerative disease [18–22].
In stroke, tissue MPO levels are routinely used to assess
neutrophil infiltration [23]. However, recent studies sug-
gest that MPO plays a detrimental role in stroke via its
ability to generate highly reactive oxidants and toxic free
radicals. Support for this idea comes from studies showing
that serum MPO levels are elevated after acute stroke
[24, 25]. Further, increased serum MPO levels in stroke
patients have been associated with white matter hyperin-
tensity, a measure of stroke severity assessed from brain
MRI scans [26]. MPO has been suggested as a biomarker
for diagnosis and prognosis of stroke [27]. A recent report
showed that 4-aminobenzoic acid hydrazide (ABAH), a
classic MPO inhibitor, reduced infarct size and neuronal
deficit in middle cerebral artery occlusion (MCAO) mice
[28]. Taken together, these reports provide strong evidence
for direct links between MPO activity and severity of brain
injury in stroke, providing the rationale for inhibiting
MPO activity as a novel therapeutic strategy for stroke.
Recently, we developed a new MPO inhibitor, N-acetyl
lysyltyrosylcysteine amide (KYC), and demonstrated that it
is a potent, reversible, specific, and non-toxic inhibitor of
MPO [29]. Specificity of KYC for inhibition of MPO has
been extensively verified in in vitro, cell models and animal
models [29, 30]. Most classic MPO inhibitors suffer high
toxicity either by inherent toxicity or yielding harmful
secondary radicals after inhibition that cause cell injury and
death (for review see [31] and [32]). However, when KYC
inhibits MPO activity, MPO can oxidize tyrosine to a po-
tent tyrosyl radical that is rapidly scavenged by nearby
cysteine to form a thiyl radical that results in the formation
of disulfides. Thus, the unique design of KYC ensures no
cell injury caused by harmful secondary radicals formed
during inhibition [29]. KYC inhibition of MPO has been
shown to improve vasodilatation in sickle cell disease mice
[33] and even inhibit tumor formation in a neutrophil-
dependent solid tumor, methylcholanthrene-initiated, butyl-
ated hydroxytoluene-promoted murine model of lung
cancer [34]. More recently, we reported that KYC reduces
disease score severity in two distinct murine models of ex-
perimental autoimmune encephalomyelitis (EAE) [30].
These studies show that KYC not only decreased oxidized
proteins and MPO levels but also restored blood-brain-
barrier (BBB) function and decreased neutrophil infiltration
in the central nervous system (CNS) of EAE mice [30]. Im-
portantly, KYC did not reduce disease scores in MPO
knockout EAE mice, demonstrating that KYC specifically
targets MPO in vivo [30]. Taken together, our findings
suggest that KYC is a specific, effective, and non-toxic
MPO inhibitor that is capable of reducing MPO-dependent
oxidative stress in the CNS. In the present study, we inves-
tigate if KYC reduces brain injury in MCAO mice and the
extent to which MPO-dependent oxidative stress mediates
brain injury and cell death after stroke.
Methods
Animal model of focal cerebral ischemia
C57BL/6J mice (8–10 weeks old) were purchased from
the Jackson Laboratory (Bar Harbor, ME). All mice were
housed in the Medical College of Wisconsin, with 12-h
light/dark cycle and allowed free access to food and water.
All animal procedures were approved by the Institutional
Animal Care and Use Committee. Animals were anesthe-
tized with 2 % isoflurane. A rectal temperature probe was
inserted to monitor and maintain a constant animal core
temperature of 37 ± 0.5 °C using a temperature controller
(TC-1000, CWE INC, Ardmore, PA). Transient focal
cerebral ischemia was induced by middle cerebral artery
occlusion (MCAO) as described by Li et al. [35]. Briefly, a
6–0 nylon monofilament suture coated with silicon-
rubber (Doccol, Sharon, MA) was inserted into the left
internal carotid artery and advanced approximately
10 mm distal to the carotid bifurcation to occlude the ori-
gin of the middle cerebral artery. The thread was carefully
withdrawn 30 min after MCAO to induce I/R injury. In
sham-operated animals, the same procedure was done
with the exception of inserting the intraluminal filament.
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During first 3 days after ischemia, the body temperature of
animals was maintained using a heating pad with Gaymar
T/pump (Stryker Inc., Kalamazoo, MI). The temperature
was set at 37 °C.
Neurobehavioral testing
Neurologic severity scores were determined by a number
of tests to assess motor, sensory, and reflex [35]. Briefly,
after raising the mouse by the tail, flexion of forelimb,
head movement >10° to vertical axis, and circling toward
paralytic side were assessed. Three more tests were per-
formed by placing the mouse on the floor to assess ab-
normal gait, circling toward the paralytic side, and
frequency of falling over. Finally, pinna reflex (a head
shake upon touching the auditory meatus) and visual
placement test (stretching of forelimbs to meet an ap-
proaching object) were also evaluated. Each test was
scored as 0 for normal and 1 for abnormal, yielding a
summed injury score from 0 to 8.
Drug administration
Groups of mice were administered either phosphate-
buffered saline (PBS) or KYC (Biomatik, Wilmington,
Delaware) 10.0 mg/kg daily intraperitoneally started
from 1 h before or 1 h after MCAO. Mice were treated
daily for 3 or 7 days after MCAO. The dosage of KYC
was determined according to the pharmacokinetics of
KYC in plasma published earlier [33] and our previous
study on the effects of KYC in a murine EAE model of
multiple sclerosis [32].
Histopathology
Three days after ischemia, mice were anesthetized and
perfused transcardially with 4 % paraformaldehyde after
pre-washing with 0.01 M PBS. Brain tissues were then
fixed in 4 % paraformaldehyde overnight and were trans-
ferred to 20 and 30 % sucrose for 1 day, respectively. Six
serial coronal slices were prepared at 1-mm intervals from
the frontal pole. Sections were cut by cryomicrotomy
(CM1900, Leica, Germany); 10-μm sections were used for
immunohistochemistry and 20-μm sections were prepared
for histological staining with 0.5 % cresyl violet [36]. The
infarct area of brain tissue was defined as the area show-
ing reduced cresyl violet staining. Data were confirmed by
light microscopy using dark pyknotic-necrotic cell bodies.
The areas of infarct and both hemispheres of each brain
section were determined using a National Institutes of
Health (NIH) ImageJ. To partially correct for effects of
edema, the corrected infarct area was determined as
described by Swanson et al. [37]: RT-LN, where RT = total
area of the right non-ischemic hemisphere, and LN = non-
infarcted area in the left ischemic hemisphere of the same
section. Lesion volume of each section was calculated as
corrected lesion area × slice thickness (1 mm). The total
lesion volume was the summation of the lesion volumes
of all brain sections.
Immunohistochemistry
The following protocol was used to determine neutro-
phil accumulation, microglia/macrophage activation, p53
expression, and neuron density in the ischemic core of
the brain cortex. Frozen sections (10 μm) were incu-
bated with 5 % goat or donkey serum in 0.01 M PBS for
1 h. The sections were incubated with rat anti-NIMP-
R14 (Abcam, Cambridge, MA; 1:50; marker of neutro-
phils), goat anti-Iba1 (Abcam; 1:200; marker of micro-
glia/macrophages), mouse anti-p53 (Abcam; 1:50), or
mouse anti-NeuN (Abcam, 1:50; marker of neuron) anti-
bodies at 4 °C, overnight. The next day, sections were
rinsed and then incubated with secondary antibodies
conjugated with Alexa Fluor 568 (1:200) for 1 h. Finally,
the sections were counterstained with DAPI to visualize
cell nuclei. To determine ClTyr or NO2Tyr accumula-
tion and colocalization with MPO, brain sections were
doubly immunostained overnight with rabbit anti-ClTyr
(Hycult Biotech, Plymouth Meeting, PA; 1:50) and
mouse anti-MPO antibodies (Hycult Biotech; 1:50) or
mouse anti-NO2Tyr (Santa Cruz, Dallas, TX; 1:50) and
rabbit anti-MPO (Abcam; 1:50) antibodies. Next, the
sections were incubated with secondary antibodies con-
jugated with Alexa Fluor 488 or 568, respectively. Com-
parable brain sections in mice from PBS and KYC
groups were selected for analysis. Images of three areas
in the cortex from three predetermined corticostriatal
sections with largest infarct profiles were captured at
random using a fluorescence microscope (DP71, Olym-
pus America Inc., Center Valley, PA). Counting of the
immunostained positive cells in each area was deter-
mined and calculated as counts per square millimeter by
a single “blind” investigator, who had no knowledge of
assignment of treatment groups using NIH ImageJ.
Endogenous IgG immunostaining was performed to
detect BBB disruption [38]. Brain sections were incu-
bated successively with peroxidase-conjugated anti-
mouse IgG antibody (Jackson ImmunoResearch, West
Grove, PA; 1:200) and 3,3′-diaminobenzidine. Gray scale
in the immunostained sections was quantified using
NIH ImageJ. IgG exudation was expressed as a percent-
age of the increase in gray scale in the ischemic hemi-
sphere: (Gi–G0)/G0 × l00%, where Gi is the gray scale of
the ischemic hemisphere and G0 is the gray scale of the
contralateral non-ischemic hemisphere.
Terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling assay
The terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling (TUNEL) assay was used to identify
apoptotic cells with nuclear DNA fragmentation in brain
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ischemic core areas. Staining was performed according to
the manufacturer’s instructions (Click-iT Plus TUNEL Kit,
Thermo Fisher, Waltham, MA). Briefly, brain sections adja-
cent to those used for immunohistochemistry were incu-
bated with proteinase K (15 min, RT) and then rinsed with
PBS. After incubation with TdT reaction buffer (10 min)
and TdT reaction mixture (1 h at 37 °C), sections were
washed and incubated with Click-iT Plus reaction cocktail
containing Alexa Fluor 488 (30 min at 37 °C). Finally, sec-
tions were counterstained with DAPI.
Western blotting
Three days after ischemia, anesthetized mice were per-
fused with PBS and brain tissues collected and stored at
−80 °C. Brain tissue proteins were extracted into radio-
immunoprecipitation assay (RIPA) buffer containing
Protease Inhibitor Cocktail and ethylenediaminetetraace-
tic acid (EDTA; Thermo Fisher Scientific, Inc., Waltham,
MA; 1: 100; v/v). Extracted proteins were separated by
SDS-PAGE and transferred to nitrocellulose membranes.
The membranes were blocked with 5 % non-fat dry milk
in tris-buffered saline and tween 20 (TBST) and subse-
quently incubated with rabbit anti- neuronal nitric oxide
synthase (nNOS) or rabbit anti-MPO antibodies (Santa
Cruz Biotechnology, Inc., Dallas, TX; 1:200) overnight at
4 °C on a rocking platform. After washing, the mem-
branes were incubated with peroxidase-conjugated anti-
rabbit IgG (Jackson; 1:5000) and protein bands were de-
tected by electrochemiluminescence (ECL) (Life Tech-
nologies, Grand Island, NY).
Statistical analysis
Data were expressed as means ± SEM. Neurological
scores were analyzed by nonparametric Mann-Whitney
test. Other statistical analyses were performed using t
test or one-way ANOVA with the appropriate post hoc
test for multiple comparisons. A p value of <0.05 was
considered statistically significant.
Results and discussion
KYC significantly reduced neurological severity scores
and infarct size in MCAO mice
We treated MCAO mice with KYC for 7 days and
determined the effects of KYC on neurological sever-
ity scores of mice after MCAO (Scheme, Fig. 1a, top
panel). PBS-treated MCAO mice group had a neuro-
logical severity score of 4.3 1 h after reperfusion
which increased to 4.8 after 1 day, then slowly de-
creased to 4.4 by day 7 (Fig. 1a, bottom panel). How-
ever, the KYC-treated group (10 mg/kg/day, started
1 h after reperfusion) had an initial score of 4.5 at
1 h which decreased to 3.0 1 day after the initial
KYC treatment and continued to decrease to 1.7 by
day 7 with continued KYC treatment (Fig. 1a, bottom
panel). As KYC is a specific inhibitor of MPO oxidant
generation, these data clearly indicate that MPO-
mediated oxidative stress plays a causal role in brain
injury and neurological deficits after stroke. To an-
swer the question whether KYC protects brains from
ischemic injury before neutrophil recruitment, mice
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Fig. 1 KYC significantly reduced neurological deficit and brain infarct
size in mice subjected to MCAO. a Effects of KYC on neurological
severity scores during 7 days after MCAO. Top panel: Experimental
scheme; KYC (10 mg/kg/day) or PBS via i.p. was administrated
starting 1 h after reperfusion. Bottom panel: Neurological severity
scores of mice after MCAO (*p < 0.05, KYC vs. PBS group at same
time interval, nonparametric Mann-Whitney test); b Effect of KYC
on infarct size in mice 3 days after MCAO. Images of brain coronal
sections (20-μm thick, 1-mm interval from rostral to caudal) by cresyl
violet stain were shown; c Infarct volume (*p < 0.05, KYC vs. PBS
group, n = 5/group, t test)
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showed that KYC pre-treatment did not reduce
neurological severity scores at 1 h post MCAO (data
not shown). These data agree with previous studies
[23, 39] showing that MPO was only detected in the
brain several hours after reperfusion and that KYC
specifically inhibits MPO activity in vivo.
Next, we investigated if KYC (10 mg/kg/day) reduces
infarct size in mice 3 days after MCAO. Coronal
sections in Fig. 1b showed that I/R injury induces a large
infarct (absence of blue staining) (left panel) [36]. KYC
treatment reduces the size of the infarct by 50 % (p <
0.05) (Fig. 1b, right panel and Fig. 1c). Taken together,
these data provide a direct link between MPO activity to
the damaged brain after stroke and that inhibiting MPO
activity is an effective therapy for preserving brain tissue.
KYC significantly protected BBB function and decreased
neutrophil infiltration
BBB dysfunction is a hallmark feature of stroke. One of the
ways to assess BBB function in vivo is to stain for tissue
IgG, which cannot enter the brain unless BBB function is
compromised [38]. Figure 2a (left panel) shows notable IgG
extravasation in the ischemic brain hemisphere of the
mouse 3 days after MCAO, which was notably reduced in
MCAO mice treated with KYC (p < 0.05) (Fig. 2a right
panel and 2b). Neutrophil infiltration is another hallmark
of stroke. Figure 2c shows that MCAO induced significant
increases in neutrophil infiltration in the ischemic hemi-
sphere of the brain as compared to the brain of the sham
mouse. KYC treatment significantly reduced neutrophil in-



































































































Fig. 2 Effects of KYC on IgG extravasation and neutrophil infiltration in the brain of MCAO mice. MCAO mice were treated with KYC (10 mg/kg/d) or
PBS via i.p. starting 1 h after MCAO. Brain tissues were harvested 3 days after MCAO. a Gross photographs of endogenous IgG extravasation in the brain
of MCAO mice. Brain coronal sections from rostral to caudal in 1-mm interval were immunostained using an anti-mouse IgG (brown); b Mean gray value
of IgG exudation (*p< 0.05, KYC vs. PBS group, t test); c Neutrophil infiltration in brain cortex ischemic core. Frozen sections were immunostained with
anti-NIMP-R14 antibody (marker for neutrophil); d Counts of NIMP-R14+ cells in the brain sections of mice 1, 3, and 7 days after MCAO; e Counts of
NIMP-R14+/MPO+ cells in the brain sections of mice 1, 3, and 7 days after MCAO (n= 4/group, p< 0.05, KYC vs. PBS group, t test)
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neutrophils (NIMP-R14+) and colocalization of MPO and
neutrophils (Additional file 1: Figure S3A). Our results
showed that both neutrophil infiltration (Fig. 2d) and MPO
+ neutrophils (Fig. 2e) were increased in MCAO brain 24 h
after MCAO and peaked at the third day. The number of
neutrophils was decreased at the seventh day after MCAO.
KYC treatment significantly reduced the number of neutro-
phils and MPO+ neutrophils in MCAO mice from day 1 to
day 7 (p < 0.05) (Fig. 2d, e). These data indicate that MPO
participates in increasing BBB leakage and that inhibiting
MPO activity restores BBB function and decreases neutro-
phil infiltration.
KYC significantly reduced microglia/macrophage
activation and neuron loss in MCAO mice
Immunofluorescent staining of brain sections showed
significant increases in Iba1+ cells (Fig. 3a–c, Additional
file 1: Figure S3B) and reductions in the number of neu-
rons in the brains of mice 3 days after MCAO (Fig. 3d, e).
Iba1+ cells and MPO expressing Iba1+ cells were increased
starting on day 1 and continued to increase through day 7.
Treating mice with KYC significantly reduced both Iba1+
cells and MPO expressing Iba1+ cells, suggesting that
MPO expression in Iba1+ cells may be regulated by MPO
activity. KYC (10 mg/kg/d) treatment also significantly re-
duced neuronal cell death (Fig. 3d, e, p < 0.05). These data
indicate that MPO-mediated oxidative stress plays import-
ant roles in microglia/macrophage activation and neuronal
cell death. However, KYC treatment has no effect on the
numbers of glial fibrillary acidic protein (GFAP)-positive
astrocytes even though MCAO increased GFAP-positive
astrocytes (Additional file 1: Figure S1).
KYC decreased apoptosis and cell injury in the brains of
MCAO mice
To investigate if inhibition of MPO reduces apoptosis in
MCAO brain, we assessed apoptosis in brain sections
using the TUNEL assay. Our results showed that the
number of TUNEL positive cells was increased in the brain







































































































Fig. 3 Effects of KYC on microglia activation and loss neuron in the brain of mice. MCAO mice were prepared as described in Fig. 2. a Images of
Iba1+ in brain cortex ischemic core 3 days after MCAO; b Counts of Iba1+ cells in the brain sections of mice 1, 3, and 7 days after MCAO. c
Counts of Iba1+/MPO+cells in the brain sections of mice 1, 3, and 7 days after MCAO. All data represented n = 4 (p < 0.05, KYC vs. PBS group, t
test). d Images of immunostaining of neuron (NeuN) in brain cortex ischemic core 3 days after MCAO; e Counts of NeuN positive cells (n = 5/
group, *p < 0.05, one-way ANOVA with Bonferroni test)
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reduced the number of TUNEL positive cells by 50 %
(Fig. 4a, c, p < 0.05). Tumor protein p53 (p53) is a key
protein for cell response to various stress induced injuries.
When cell injury occurs after stress, p53 is expressed and
nuclear translocated, which leads to activating the repair of
damaged cells, or to trigger apoptosis in injured cells where
DNA damage is irreparable [40]. Since TUNEL assay may
not be absolutely specific for apoptosis [41, 42], we deter-
mined p53 expression in cell nuclei. We found that p53
accumulation in nucleus in the brain of MCAO mice was
significantly increased and KYC treatment reduced the p53
accumulation by 70 % (Fig. 4b, d, p < 0.05). Further study
showed that 86.3 ± 0.3 % p53+ cells were colocalized with
TUNEL+ cells in the sections of the brain from MCAO
mice. Taken together, our results strongly suggested that
KYC protects CNS cells from MPO-mediated apoptosis.
Additional evidence that KYC reduced brain injury in
MCAO mice comes from western blots of nNOS in brains
(Fig. 4e, f) [43]. nNOS western blots show that MACO
significantly reduced nNOS levels 3 days after MCAO
(Fig. 4f, p < 0.05) and that KYC treatment markedly
increased nNOS levels in the brains of MCAOmice (Fig. 4f,
p < 0.01).
KYC reduced MPO in the brains of MCAO mice
To investigate if KYC also reduces the amount of MPO in
the brains of MCAO mice, we analyzed MPO levels in the
brains of mice 3 days after MCAO using western blot. Our
data showed that MCAO induced a large increase of MPO
levels in brain tissues (Fig. 5a) that was decreased in the
brains of KYC-treated MCAO mice (Fig. 5a). Immunohis-
tological studies also showed marked increases in MPO in
brain sections from PBS-treated MCAO mice, which was
significantly reduced by KYC treatment (Fig. 5b, e). Further
analyses of MCAO tissues from day 1, 3, and 7 showed that
both MPO activity and MPO immunostaining were in-
creased in MCAO brain and peaked at third day after
MCAO (Additional file 1: Figure S2A and S2B).
To confirm that KYC reduces MPO-dependent dam-
age by inhibiting MPO activity, we probed the brain sec-
tions for ClTyr, a fingerprint biomarker of MPO activity.




















































































Sham            PBS           KYC  
Fig. 4 Effects of KYC on apoptosis in the brain of mice 3 days after MCAO. MCAO mice were prepared as described in Fig. 2. a Images of TUNEL assay in
the cortex ischemic core areas; b Images of p53 immunostaining in brain cortex ischemic core; blue: DAPI, red: p53, and purple: p53 +DAPI, as arrows
indicated. c Counts of TUNEL positive cells (n= 5/group, *p< 0.05, KYC vs. PBS group, t test). d Counts of p53 positive cells (n= 4/group, *p< 0.05, KYC vs.
PBS group, t test). e Western blot of nNOS in MCAO brains; f Density analysis of nNOS western blot. The data shown is the ratio of nNOS density to β-actin
density. The data for sham group is normalized to 100 % (n= 6/group, one-way ANOVA with Bonferroni test, *p< 0.05 and **p< 0.01)
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of sham, PBS- and KYC-treated MCAO brain sections.
Compared to sham, PBS-treated brains had marked in-
crease in ClTyr immunostaining. In contrast, ClTyr for-
mation was significantly reduced in KYC-treated MCAO
mice (~65 %, Fig. 5c, f ). Moreover, double immunofluor-
escent staining revealed ClTyr colocalized with MPO (or-
ange-yellow) in the brains of MCAO mice and that KYC
treatment essentially ablated colocalization (Fig. 5d).
These data indicate KYC effectively inhibits MPO activity
and MPO generation of toxic oxidants in MCAO brains.
KYC reduced NO2Tyr and 4-HNE in MCAO mice
MPO is known to generate a wide variety of free radicals
that form stable adducts during oxidation of protein and
lipids such as NO2Tyr and 4-HNE. To determine if MPO
increases the formation of these stable oxidation products,
sections of the brains were immunostained with antibodies
that were specific for NO2Tyr and 4-HNE. Figure 6a shows
that NO2Tyr immunostaining was markedly increased in
the brains of mice 3 days after MCAO. KYC treatment of







































































Fig. 5 Effects of KYC on MPO and ClTyr expression in the brain of mice 3 days after MCAO. MCAO mice were prepared as described in Fig. 2. a Western
blot of MPO in brain tissues of MCAO mice; b Images of MPO immunostaining in cortex ischemic core areas; c ClTyr immunostaining in the cortex
ischemic core areas; d Images of colocalization of MPO and ClTyr in brain cortex ischemic core; red: ClTyr, green: MPO, and yellow: ClTyr +MPO, as arrows
indicated. All images here are the representative images of five repeat samples. e Counts of MPO positive cells (n= 5/group, *p< 0.05, KYC vs. PBS group, t
test). f Counts of ClTyr positive cells (n= 5/group, *p< 0.05, KYC vs. PBS group, t test)
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(Fig. 6e). Figure 6b shows that NO2Tyr co-localizes with
MPO in MCAO brains (orange-yellow). These data indicate
that MPO plays a major role in nitrosative damage in the
brains of MCAO mice. 4-NHE was also increased in
MCAO mice, which was significantly reduced with KYC
treatment (Fig. 6c, f). Moreover, 4-HNE co-localizes with
MPO in the brains of MCAO mice (Fig. 6d). Together, the
data demonstrate that MPO-dependent oxidative stress sig-
nificantly contributes to brain damage in MCAO mice.
This report shows that KYC, a novel competitive in-
hibitor of MPO, reduces oxidative damage to brains in
an established murine model of stroke. In summary, our
studies show that the benefits of targeting MPO-dependent
oxidative stress are reductions in neurological severity
scores, infarct size, BBB leakage, neutrophil infiltration,
microglia/macrophage activation, neuronal loss, and apop-
tosis in the core of the lesions. Here, we provide direct evi-
dence showing that KYC specifically inhibits MPO activity
in MCAO mice based on (1) the fact that KYC decreases
ClTyr formation, a molecular fingerprint of MPO oxidative
activity and (2) the fact that ClTyr colocalization with MPO
confirms that KYC targets MPO activity as we reported
earlier [33]. Data here demonstrate that MPO-mediated
oxidative stress plays a causal role in the mechanisms driv-
ing brain injury after stroke.
It is important to note that KYC did not reduce neuro-
logical scores after 1-h reperfusion when it was used to








































































Fig. 6 Effects of KYC on NO2Tyr and 4-HNE expression in the brain of mice 3 days after MCAO. MCAO mice were prepared as described in Fig. 2. a
Images of NO2Tyr immunostaining in the cortex ischemic core areas; b Images of colocalization of MPO and NO2Tyr in brain cortex ischemic core; red:
NO2Tyr, green: MPO, and yellow: NO2Tyr +MPO, as arrows indicated; c 4-HNE immunostaining in the cortex ischemic core areas; d Images of colocalization
of 4-HNE and MPO in brain cortex ischemic core (red: 4-HNE, green: MPO, and yellow: 4-HNE +MPO, as arrows indicated). All images are the representative
images of five repeat samples. e Counts of NO2Tyr positive cells (n= 5, * p< 0.05, KYC vs. PBS group, t test). f Counts of 4-HNE positive cells (n= 5, * p<
0.05, KYC vs. PBS group, t test)
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MPO was not present during the period of ischemia and
early reperfusion after stroke. Previous reports have
shown that the increase of MPO in stroke occurs 6–
12 h after ischemic injury [23, 39]. Thus, data here agree
with our previous report showing that KYC specifically
targets MPO in an EAE model of multiple sclerosis [30].
Our study showed that inhibiting MPO activity signifi-
cantly reduced MPO activity and MPO protein in
MCAO brain (Fig. 5a, b and Additional file 1: Figure S2)
which is consistent with our published report showing
that KYC treatment reduces the amount of MPO in the
CNS of EAE mice [30]. The reason for such a change
might be due to a decrease of neutrophil infiltration as
well as microglia/macrophage activation. We found that
MPO-dependent oxidative stress plays a major role in
damaging BBB in MCAO mice during reperfusion
(Fig. 2a) [30]. Inhibition of MPO reduced BBB leakage,
which can also decrease neutrophil infiltration (Fig. 2c–e)
as well as decrease the amount of MPO that can enter
damaged MCAO brains. Another way KYC may decrease
MPO in MCAO brains is inhibiting MPO activity, which
reduces Iba+/MPO+ cells (Fig. 3a–c). These data are con-
sistent with data from others who showed that MPO
activity induces activated microglial cells/macrophages in
MCAO brains to express MPO [44]. Accordingly, both a
decrease in neutrophil infiltration and a reduction in
microglia/macrophage activation by KYC treatment could
contribute to significant reductions in MPO in the brains
of MCAO mice.
Although there is overwhelming evidence for oxidative
stress playing a role in neuronal damage induced by stroke,
clinical trials have failed to show that antioxidants improve
outcomes in stroke patients [45, 46]. Moreover, some large
clinical trials have concluded that antioxidant supplementa-
tion could even be harmful [13–15]. Several reasons have
been proposed to explain why previous antioxidant clinical
trials did not work [13–15]. Generally, the reaction rates
between antioxidants and ROS are slower than the rates be-
tween biological molecules and ROS. Secondly, although
antioxidants scavenge free radicals in vivo, the oxidized
products of antioxidants can become harmful free radicals
that also cause tissue damage. Moreover, recent studies
have found that ROS play important roles as signaling mol-
ecules under normal physiological conditions. ROS become
detrimental in many diseases only when there is an over-
production of ROS that causes oxidative stress in vivo. Ac-
cordingly, using non-specific antioxidants could interfere
with the beneficial effects of ROS required for normal
physiological function. To overcome problems associated
with antioxidant therapy, it was suggested that inhibitors
targeting oxidant formation from specific sources is what is
needed to reduce oxidative stress in stroke [47]. Here, using
an established MCAO murine model of stroke, we show
that KYC, an MPO-specific inhibitor, effectively reduces
brain injury after stroke. Indeed, just 3 days of KYC treat-
ment was sufficient to significantly reduce infarct size, BBB
dysfunction, neutrophil infiltration, and neuronal cell death.
Our results strongly support the idea that targeting of spe-
cific oxidative sources, in this case, MPO with KYC, is an
effective therapeutic strategy for treating stroke patients.
Previous studies have shown that oxidation products
were increased in stroke patients and animal models
[6, 9, 10, 24, 48–56]. It is well known that nNOS is acti-
vated and iNOS expression is upregulated after I/R treat-
ment [57–59]. NO2Tyr was found to be increased in
both the core and surrounding penumbra after ischemia
and even further increased during reperfusion in animal
models of stroke [6, 50, 51]. The formation of NO2Tyr
in stroke has been largely attributed to peroxynitrite for-
mation [58, 60]. However, our experiments show that
NO2Tyr formation is significantly reduced by KYC
(Fig. 6). The fact that NO2Tyr can be co-localized with
MPO in MCAO mice brains suggests that MPO-
mediated nitration is a major pathway for NO2Tyr for-
mation after stroke. Lipid peroxidation products are also
significantly increased in the plasma of stroke patients
(14–19). Our data show that KYC reduced 4-HNE, a
stable lipid peroxidation product, in the brains of
MCAO mice (Fig. 6). Such data indicate that MPO-
dependent oxidation may also increase the generation of
lipid peroxidation products. Taken together, this study
clearly suggests that MPO-dependent oxidative stress
plays an important role in oxidative injury of the brain
after stroke and that inhibiting MPO oxidant production
could be an effective therapeutic strategy for reducing
oxidative stress and decreasing brain injury in stroke
patients.
Conclusions
KYC, a specific competitive inhibitor of MPO activity, ef-
fectively inhibits MPO generation of toxic oxidants in vivo.
By doing so, KYC reduces neuronal damage and preserves
brain tissue and neurological function in the stroked brain.
On the basis of these findings, we conclude that MPO-
mediated oxidative stress plays an important role in the
mechanisms by which stroke induces oxidative injury to
the brain and accordingly KYC should be a highly effective
therapeutic agent for treating patients with stroke.
Additional file
Additional file 1: Figure S1. Effect of KYC on astrocytes activation in
the brain of mice 3 days after MCAO. Mice were treated with PBS or
KYC (10 mg/kg/d) via i.p. starting 1 h after MCAO. A. Images of
immunostaining of astrocytes (GFAP) in brain cortex ischemic core; B.
Counts of GFAP-positive cells. Figure S2. The changes of MPO activity
and protein in the brain of mice after MCAO. MCAO mice were prepared
as described in Fig. 2 and brain tissues were harvested 1, 3, and 7 days
after MCAO. A. MPO activity. MPO in samples was extracted as follows
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[61]: Brain tissues were homogenized in 0.1 M potassium phosphate
buffer pH 6.0 containing 0.5 % cetyltrimethylammonium bromide.
The samples were ultrasonicated for 30 s and went through three
freeze-thaw cycles. Finally, the samples were centrifuged at 15,000g for
15 min and supernatants were saved for MPO activity assay. MPO
activity assay was performed based on our previously published
method with modifications [30]: Briefly, extracted samples were mixed
with 50 mM sodium phosphate buffer pH 5.4 containing 100 μM
diethylenetriaminepentaacetic acid, 10 mM NaNO2, 100 μM hydrogen
peroxide, and 50 μM Amplex Ultra Red. After incubation at 37 °C for
15 min, the fluorescence intensity was measured at ex = 540 nm,
em = 590 nm. All data represents n = 3/group. Sham were from day 1, 3,
7 (n = 3/group). (*p < 0.05 and ***p < 0.001, KYC vs. PBS group, t test). B.
Counts of MPO+ cells in cortex ischemic core area. (n = 4/group; *p <
0.05, KYC vs. PBS, t test). Figure S3. Effects of KYC on the expression of
MPO in NIMP-R14 and Iba1 positive cells in the cortex ischemic core
areas of mice after MCAO. MCAO mice were prepared as described in
Fig. 2 and brain tissues were harvested 1, 3, and 7 days after MCAO. A.
Images of immunostaining of MPO+ and NIMP-R14+ cells (green: MPO,
red: NIMP-R14, and yellow: MPO + NIMP-R14, as arrows indicated). B.
Images of immunostaining of MPO+ and Iba1+ cells (green: MPO, red:
Iba1, and yellow: MPO + Iba1, as arrows indicated). All images here
are the representative images of four repeat samples. Figure S4.
Colocalization of p53 immunostaining with TUNEL positive cells in brain
cortex ischemic core of mice 3 days after MCAO. Red: p53, green: TUNEL,
yellow: p53 + TUNEL, as arrows indicated. Images represent three repeats.
(PDF 586 kb)
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